Young women who were vaccinated against human papillomavirus (HPV) in their teens with an older GlaxoSmithKline product called Cervarix had up to an 87% lower risk of developing cervical cancer linked to the virus, a long-running English study found. When the vaccinated women were in their 20s, those who had received the series of shots between ages 12 and 13 had cervical
New data from England show the success of the national human papillomavirus (HPV) vaccination program in preventing cervical cancer and noninvasive precursor lesions in young women.